ALS Center Karolinska

Karolinska Institutet

The ALS Center Karolinska is a tertiary center for ALS and provides multidisciplinary care to ALS patients from the Greater Stockholm region. The Center also provides second opinion referrals from other Swedish patients and from ALS patients abroad. The Center conducts clinical trials for ALS via the ALS Treatment Center Karolinska (ALS Treat).

KarolinskaInstitutet_Logo
Karolinska Institutet

At the ALS Center Karolinska, we integrate clinical care with clinical- and preclinical research. Our main research focus is epidemiological research, risk and prognosis, quality of life, wet and dry biomarkers. All patients are part of the national Swedish MND registry, which is based in our clinic. To give patients and their families an opportunity to participate in clinical trials, the ALS Treatment Center Karolinska (ALS Treat) was established in cooperation with the clinic and conducts several clinical trials of ALS.

Contact
Location
Karolinska Universitetssjukhuset Huddinge, 18146, Stockholm, Sweden

Our Specialists

Caroline Ingre

Neurologist and Researcher

Dr. Caroline Ingre is a specialist in neuromuscular disease, and has been […]

Caroline Ingre
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more